Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT07213544

Remimazolam vs Propofol in Laser Burn Cases

Led by Medical University of South Carolina · Updated on 2025-11-20

136

Participants Needed

1

Research Sites

59 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust/chin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \< 8).

CONDITIONS

Official Title

Remimazolam vs Propofol in Laser Burn Cases

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age ≥ 18 years
  • Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy
Not Eligible

You will not qualify if you...

  • History of previous fractional ablative laser therapy for burn scar
  • Procedure expected to last longer than 30 minutes
  • Allergy such as dextran 40 or contraindication to either of the study drugs
  • Pregnant and/or breastfeeding
  • Subjects who are unable to or choose not to give informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

Actively Recruiting

Loading map...

Research Team

H

Haley Nitchie

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here